[{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Non-viral Based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intergalactic Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Intergalactic Therapeutics \/ ATP","highestDevelopmentStatusID":"2","companyTruncated":"Intergalac.."},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IG-002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intergalactic Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Intergalactic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Intergalac.."}]

Find Clinical Drug Pipeline Developments & Deals by Intergalactic Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : IG-002 addresses all forms of ABCA4-related retinopathies, a subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable (12-month) expression of human ABCA4 protein in ad...

                          Product Name : IG-002

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          March 15, 2023

                          Lead Product(s) : IG-002

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Non-viral Based Gene Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Partner/Sponsor/Collaborator : ATPGroup

                          Deal Size : $75.0 million

                          Deal Type : Series A Financing

                          Details : Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically ad...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 07, 2021

                          Lead Product(s) : Non-viral Based Gene Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Partner/Sponsor/Collaborator : ATPGroup

                          Deal Size : $75.0 million

                          Deal Type : Series A Financing

                          blank